rucaparib | Rucaparib

Keyword	CPC	PCC	Volume	Score	Length of keyword
rucaparib	1.52	0.7	7212	77	9

Keyword	CPC	PCC	Volume	Score
rucaparib	1.25	0.6	8874	27
rucaparib package insert	1.91	1	6294	91
rucaparib fachinformation	1.27	0.9	6224	98
rucaparib smpc	0.25	0.8	6612	38
rucaparib spc	0.67	0.8	5453	96
rucaparib fda	1.43	0.4	7709	73
rucaparib side effects	0.92	1	9977	95
rucaparib camsylate	0.27	0.9	3581	10
rucaparib prostate cancer	0.31	0.9	9114	9
rucaparib fda label	0.88	0.2	4357	30
rucaparib ema	0.95	0.9	2609	7
rucaparib fda approval	1.76	0.1	4886	36
rucaparib ovarian cancer	1.37	0.3	6580	99
rucaparib pi	1.04	0.8	2382	44
rucaparib prescribing information	1.31	0.3	3864	20
rucaparib fda approval history	1.1	0.2	1519	12
rucaparib fda package insert	1.84	0.3	4218	31
rucaparib fda label 2023	1.92	0.1	8617	95
rucaparib fda prostate	1.21	0.3	1460	14
rucaparib fda approval ovarian cancer	0.2	0.9	6765	86

Search Results related to rucaparib on Search Engine

Rucaparib - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Rucaparib

WEBRucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth.

DA: 70 PA: 52 MOZ Rank: 71

Rucaparib | FDA - U.S. Food and Drug Administration
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/rucaparib

WEBThe recommended dose and schedule for rucaparib is 600 mg (two 300 mg tablets) taken orally twice daily with or without food. FDA granted the rucaparib application breakthrough therapy...

DA: 35 PA: 4 MOZ Rank: 1

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

WEBFeb 16, 2023 · In a phase 2 study, rucaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), showed a high level of activity in patients who had metastatic, castration-resistant prostate cancer associated...

DA: 7 PA: 13 MOZ Rank: 13

Rucaparib: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB12332

WEBRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. 1 Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality.

DA: 63 PA: 68 MOZ Rank: 49

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652254/

WEBSep 15, 2022 · Rucaparib is an oral small-molecule poly (ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated with a deleterious BRCA1 or BRCA2 mutation.

DA: 94 PA: 60 MOZ Rank: 23

Rubraca | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca

WEBOct 10, 2018 · It is used as maintenance treatment in patients newly diagnosed with advanced cancer or in patients whose cancer has come back, and in whom the cancer has cleared (partially or completely) after treatment with platinum-based chemotherapy. Rubraca contains the active substance rucaparib.

DA: 44 PA: 78 MOZ Rank: 61

Rucaparib (Rubraca) | Cancer information | Cancer Research UK
cancerresearchuk.org

https://www.cancerresearchuk.org/about-cancer/treatment/drugs/rucaparib

WEBSep 11, 2023 · How does rucaparib work? Rucaparib is a targeted drug called a PARP inhibitor. PARP is a protein that helps damaged cells to repair themselves. Rucaparib stops PARP working. Some cancer cells rely on PARP to keep their DNA healthy. This includes cancer cells with a change in the BRCA genes.

DA: 9 PA: 19 MOZ Rank: 11

Rucaparib: the past, present, and future of a newly approved …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488752/

WEBJun 19, 2017 · Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies demonstrated clinical efficacy in both BRCA -mutated (inclusive of germline and somatic) ovarian tumors and ovarian tumors with homologous recombination deficiency (HRD) loss of heterozygosity …

DA: 66 PA: 45 MOZ Rank: 14

Rucaparib Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/rucaparib.html

WEBJan 13, 2023 · What is rucaparib? Rucaparib is used to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (cancer of the membrane lining the organs inside your abdomen). Rucaparib is sometimes used for these conditions only if your cancer has a specific genetic marker (an abnormal "BRCA" gene). Your doctor will test you for this gene.

DA: 8 PA: 55 MOZ Rank: 58

Rucaparib: MedlinePlus Drug Information
medlineplus.gov

https://medlineplus.gov/druginfo/meds/a617002.html

WEBRucaparib is used to help maintain the response to other treatments for certain types of ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer that has ...

DA: 4 PA: 39 MOZ Rank: 31